JASN: Risk of AKI and major adverse clinical outcomes in patients with Severe Acute Respiratory Syndrome or Neo-Coronary Pneumonia

Severe Acute Respiratory Syndrome (SARS) is closely related to neo-coronary pneumonia (COVID-19).
but the impact of AKI on the clinical outcomes of both diseases is not yet clear.
recently, a retrospective, full-queue study using the Hong Kong Electronic Public Health Database identified SARS or COVID-19 patients through diagnostic codes, virological test results, or a combination of both, in a research paper published in Journal of the American Society of Nephrology, an authoritative journal in the field of kidney disease.
main endpoint of the study was a combination of hospital stay in the intensive care unit, the use of invasive mechanical aeration, and/or death.
identified 1,670 SARS patients and 1,040 COVID-19 patients (the middle age was 41 and 35 years, respectively).
in SARS patients, 26% reached the primary endpoint, while in COVID-19 patients 5.3%.
, liver abnormalities, and AKI were significantly associated with the main endpoints of SARS or COVID-19 patients.
in SARS patients, 7.9%, 2.1% and 3.7% had stage 1, stage 2 and stage 3 AKI, respectively.
in the COVID-19 population, 6.6 per cent, 0.4 per cent and 1.1 per cent, respectively, occurred in stages 1, 2 and 3 AKI.
in both groups, factors significantly associated with AKI included diabetes and high blood pressure.
in AKI patients, the risk of major adverse clinical outcomes was lower in COVID-19 patients than in SARS patients.
kidney function usually occurs within 30 days of the AKI event.
result, the AKI rate of SARS patients was higher than that of COVID-19 patients.
AKI was associated with major adverse clinical outcomes in patients with both diseases.
with diabetes and liver abnormalities had an increased risk of severe outcomes after SARS and COVID-19 infections.